Profile: AbbVie Inc (ABBV.K)

ABBV.K on New York Consolidated

54.41USD
20 Oct 2014
Price Change (% chg)

$1.04 (+1.95%)
Prev Close
$53.37
Open
$52.56
Day's High
$54.59
Day's Low
$52.25
Volume
17,954,637
Avg. Vol
14,174,427
52-wk High
$60.02
52-wk Low
$45.50

Search Stocks

AbbVie Inc. (AbbVie), incorporated on April 10, 2012, is a research-based pharmaceuticals company. The Company discovers, develops, and commercializes advanced therapies. AbbVie's portfolio of products include a line of adult and pediatric pharmaceuticals, which includes HUMIRA, metabolics/hormones products, virology products, endocrinology products, dyslipidemia products and other products.

AbbVie products are used to treat rheumatoid arthritis, psoriasis, Crohn's disease, human immunodeficiency virus (HIV), cystic fibrosis complications, low testosterone, thyroid disease, Parkinson's disease and complications associated with chronic kidney disease, among other indications. In October 2012, AbbVie initiated a comprehensive Phase III program for hepatitis C virus (HCV) genotype one.

Company Address

AbbVie Inc

1 N Waukegan Rd
NORTH CHICAGO   IL   60064-1802
P: +1847.9327900
F: +1302.6555049

Search Stocks